Furthermore, elevated DHHC9 expression was significantly associated with poor clinical outcomes in colorectal cancer, lung adenocarcinoma, gastric cancer, pancreatic cancer and rectal adenocarcinoma (Figure 1H). Here, ZDHHC9 is linked to pancreatic neoplasm.